Novartis

Novartis is a global healthcare company based in Switzerland that provides solutions to address the evolving needs of patients worldwide.

We apply our expertise in science and innovation to society’s biggest health challenges. Responsibility is a core part of our business strategy.
Company growth
Type
Public
HQ
Basel, CH
Founded
1996
Size (employees)
118,393 (est)
Novartis was founded in 1996 and is headquartered in Basel, CH

Key People at Novartis

Joseph Jimenez

Joseph Jimenez

Chief Executive Officer
Harry Kirsch

Harry Kirsch

Chief Financial Officer
Paul van Arkel

Paul van Arkel

Head of Corporate Strategy and Healthcare Systems
Peter Elam

Peter Elam

Head of Internal Audit
Erwin Vanhaecke

Erwin Vanhaecke

Head Novartis Group Quality
Michael Willi

Michael Willi

Group Head of Communications
Felix Ehrat

Felix Ehrat

Group General Counsel
Richard Francis

Richard Francis

CEO, Sandoz
Andre Wyss

Andre Wyss

President, Novartis Operations Country President for Switzerland
Juergen Brokatzky-Geiger

Juergen Brokatzky-Geiger

Global Head, Corporate Responsibility for Novartis
Michael Ball

Michael Ball

CEO, Alcon
James Bradner

James Bradner

President, Novartis Institutes for BioMedical Research
Paul Hudson

Paul Hudson

CEO, Novartis Pharmaceuticals
Bruno Strigini

Bruno Strigini

CEO, Novartis Oncology
Steven Baert

Steven Baert

Head of Human Resources

Novartis Office Locations

Novartis has offices in Basel, East Hanover, New York, Wehr and in 2 other locations
Basel, CH
East Hanover, US
New York, US
Wehr, DE
Tokyo, JP
Beijing, CN

Novartis Metrics

Novartis Summary

Market capitalization

$175 B

Closing share price

$72.3
Novartis's current market capitalization is $175 B.

Novartis Financials

Novartis's revenue is $48.5 B in FY, 2016 which is 1.81% decrease from the previous period.
FY, 2016FY, 2015FY, 2014

Revenue

$48.5 B$49.4 B$53.6 B

Revenue growth, %

-1.8%-7.9%

Cost of goods sold

$17.5 B$17.4 B$17.3 B

Gross profit

$31.9 B$33 B$36.3 B

Gross profit Margin, %

65.8%66.7%67.7%

Sales and marketing expense

$12 B$11.8 B$12.4 B

R&D expense

$9.04 B$8.94 B$9.09 B

General and administrative expense

$2.19 B$2.48 B$2.62 B

Operating expense total

$23.6 B$24 B$25.2 B

Interest expense

$-707 M$-655 M$-704 M

Interest income

$-447 M$-454 M$-31 M

Net Income

$6.7 B$17.8 B$10.3 B

Operating cash flow

$11.5 B$12.1 B

Novartis Operating Metrics

Y, 2016Y, 2015

Patients reached

965 M972 M

Projects entering development pipeline

58

Major submissions (US, EU, JP)

2414

Major approvals (US, EU, JP)

1620

US FDA breakthrough therapy designations

50

Ongoing Phase III programs

2937

Novartis Market Value History

Novartis Revenue Breakdown

Novartis Online Presence

Novartis News

Novartis Company Life

You may also be interested in